Literature DB >> 17880000

How to distinguish healthy from diseased? Classification strategy for mass spectrometry-based clinical proteomics.

Margriet M W B Hendriks1, Suzanne Smit, Wies L M W Akkermans, Theo H Reijmers, Paul H C Eilers, Huub C J Hoefsloot, Carina M Rubingh, Chris G de Koster, Johannes M Aerts, Age K Smilde.   

Abstract

SELDI-TOF-MS is rapidly gaining popularity as a screening tool for clinical applications of proteomics. Application of adequate statistical techniques in all the stages from measurement to information is obligatory. One of the statistical methods often used in proteomics is classification: the assignment of subjects to discrete categories, for example healthy or diseased. Lately, many new classification methods have been developed, often specifically for the analysis of X-omics data. For proteomics studies a good strategy for evaluating classification results is of prime importance, because usually the number of objects will be small and it would be wasteful to set aside part of these as a 'mere' test set. The present paper offers such a strategy in the form of a protocol which can be used for choosing among different statistical classification methods and obtaining figures of merit of their performance. This paper also illustrates the usefulness of proteomics in a clinical setting, serum samples from Gaucher disease patients, when used in combination with an appropriate classification method.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880000     DOI: 10.1002/pmic.200700046

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  14 in total

1.  Infant Viral Respiratory Infection Nasal Immune-Response Patterns and Their Association with Subsequent Childhood Recurrent Wheeze.

Authors:  Kedir N Turi; Jyoti Shankar; Larry J Anderson; Devi Rajan; Kelsey Gaston; Tebeb Gebretsadik; Suman R Das; Cosby Stone; Emma K Larkin; Christian Rosas-Salazar; Steven M Brunwasser; Martin L Moore; R Stokes Peebles; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2018-10-15       Impact factor: 21.405

2.  A comparison of methods for classifying clinical samples based on proteomics data: a case study for statistical and machine learning approaches.

Authors:  Dayle L Sampson; Tony J Parker; Zee Upton; Cameron P Hurst
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

3.  Swarm intelligence based wavelet coefficient feature selection for mass spectral classification: an application to proteomics data.

Authors:  Weixiang Zhao; Cristina E Davis
Journal:  Anal Chim Acta       Date:  2009-08-15       Impact factor: 6.558

4.  HDL in humans with cardiovascular disease exhibits a proteomic signature.

Authors:  Tomás Vaisar; Philip Mayer; Erik Nilsson; Xue-Qiao Zhao; Robert Knopp; Bryan J Prazen
Journal:  Clin Chim Acta       Date:  2010-03-20       Impact factor: 3.786

5.  The E3 ligase COP1 promotes ERα signaling and suppresses EMT in breast cancer.

Authors:  Kateryna Shostak; Alain Chariot; Seng Chuan Tang; Quentin Lion; Olivier Peulen; Philippe Chariot; Arnaud Lavergne; Alice Mayer; Paula Allepuz Fuster; Pierre Close; Sebastian Klein; Alexandra Florin; Reinhard Büttner; Ivan Nemazanyy
Journal:  Oncogene       Date:  2021-10-29       Impact factor: 9.867

Review 6.  Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders.

Authors:  Wenping Li; Stephanie M Cologna
Journal:  Mol Omics       Date:  2022-05-11

7.  Finding biomarker signatures in pooled sample designs: a simulation framework for methodological comparisons.

Authors:  Anna Telaar; Gerd Nürnberg; Dirk Repsilber
Journal:  Adv Bioinformatics       Date:  2010-07-04

8.  Sub-typing of rheumatic diseases based on a systems diagnosis questionnaire.

Authors:  Herman A van Wietmarschen; Theo H Reijmers; Anita J van der Kooij; Jan Schroën; Heng Wei; Thomas Hankemeier; Jacqueline J Meulman; Jan van der Greef
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

9.  Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements.

Authors:  Herman A van Wietmarschen; Weidong Dai; Anita J van der Kooij; Theo H Reijmers; Yan Schroën; Mei Wang; Zhiliang Xu; Xinchang Wang; Hongwei Kong; Guowang Xu; Thomas Hankemeier; Jacqueline J Meulman; Jan van der Greef
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

10.  Classification-based comparison of pre-processing methods for interpretation of mass spectrometry generated clinical datasets.

Authors:  Wouter Wegdam; Perry D Moerland; Marrije R Buist; Emiel Ver Loren van Themaat; Boris Bleijlevens; Huub Cj Hoefsloot; Chris G de Koster; Johannes Mfg Aerts
Journal:  Proteome Sci       Date:  2009-05-14       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.